GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Smruthi Organics Ltd (BOM:540686) » Definitions » Quality Rank

Smruthi Organics (BOM:540686) Quality Rank


View and export this data going back to 2005. Start your Free Trial

What is Smruthi Organics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Smruthi Organics Quality Rank Related Terms

Thank you for viewing the detailed overview of Smruthi Organics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Smruthi Organics (BOM:540686) Business Description

Traded in Other Exchanges
N/A
Address
165-A, Balaji Bhavan, 1st Floor, Railway Lines, Solapur, MH, IND, 413 001
Smruthi Organics Ltd is engaged in the manufacture of bulk drugs and drug intermediates (API Products). The product portfolio includes Amlodipine Besilate, Amlodipine Base, S-Amlodipine Besilate, S-Amlodipine Base, Norfloxacin, Metformin HCI, Diloxanide Furoate, Phthaloyl Amlodipine, Pantoprazole Sodium, Pefloxacin Mesylate Dihydrate, Telmisartan, Losartan Potassium and many more. It has two segments Bulk Drugs and Drugs Intermediates (API) and Formulation. it generates the majority of its revenue from the Bulk Drugs and Drugs Intermediates (API) segment.